Robeco Institutional Asset Management B.V. Has $62.43 Million Stock Holdings in Biogen Inc. (NASDAQ:BIIB)

Robeco Institutional Asset Management B.V. increased its stake in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 48.6% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 408,276 shares of the biotechnology company's stock after purchasing an additional 133,568 shares during the period. Robeco Institutional Asset Management B.V. owned approximately 0.28% of Biogen worth $62,434,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in BIIB. Ashton Thomas Securities LLC acquired a new stake in shares of Biogen during the third quarter worth about $33,000. Venturi Wealth Management LLC lifted its holdings in Biogen by 73.8% during the 3rd quarter. Venturi Wealth Management LLC now owns 219 shares of the biotechnology company's stock worth $42,000 after buying an additional 93 shares in the last quarter. Itau Unibanco Holding S.A. grew its stake in shares of Biogen by 63.8% in the third quarter. Itau Unibanco Holding S.A. now owns 231 shares of the biotechnology company's stock worth $45,000 after acquiring an additional 90 shares in the last quarter. FSA Wealth Management LLC acquired a new position in shares of Biogen in the third quarter worth $74,000. Finally, TD Private Client Wealth LLC increased its position in shares of Biogen by 25.0% during the third quarter. TD Private Client Wealth LLC now owns 385 shares of the biotechnology company's stock worth $75,000 after acquiring an additional 77 shares during the period. Institutional investors and hedge funds own 87.93% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on BIIB. Robert W. Baird upped their price target on Biogen from $294.00 to $300.00 and gave the company an "outperform" rating in a report on Friday, November 15th. JPMorgan Chase & Co. dropped their target price on Biogen from $220.00 to $210.00 and set a "neutral" rating on the stock in a research report on Monday, November 4th. Needham & Company LLC downgraded Biogen from a "buy" rating to a "hold" rating and set a $270.00 price target on the stock. in a research note on Monday, November 18th. Morgan Stanley cut Biogen from an "overweight" rating to an "equal weight" rating and cut their price objective for the stock from $285.00 to $204.00 in a research report on Thursday, October 31st. Finally, Citigroup lowered their price target on shares of Biogen from $190.00 to $160.00 and set a "neutral" rating on the stock in a research note on Tuesday. Sixteen analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $228.80.

Biogen Stock Up 1.3 %

Shares of BIIB stock traded up $1.82 during mid-day trading on Thursday, reaching $146.23. 1,110,748 shares of the company were exchanged, compared to its average volume of 1,282,402. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.80 and a current ratio of 1.26. The business's 50 day simple moving average is $151.32 and its 200 day simple moving average is $179.80. The company has a market capitalization of $21.31 billion, a P/E ratio of 13.21, a P/E/G ratio of 1.64 and a beta of -0.07. Biogen Inc. has a fifty-two week low of $139.71 and a fifty-two week high of $251.99.

Biogen (NASDAQ:BIIB - Get Free Report) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $4.08 earnings per share for the quarter, topping the consensus estimate of $3.77 by $0.31. Biogen had a net margin of 16.81% and a return on equity of 14.98%. The company had revenue of $2.47 billion during the quarter, compared to analyst estimates of $2.43 billion. During the same period last year, the business earned $4.36 EPS. The firm's revenue for the quarter was down 2.5% compared to the same quarter last year. Research analysts predict that Biogen Inc. will post 16.41 earnings per share for the current year.

Biogen Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.